Logo
x

Search

Subscribe Now

everest medicines

Everest Medicines Reports Results from the P-Ib/IIa Study of EVER001 to Treat Primary Membranous Nephropathy

Everest Medicines Reports Results from the P-Ib/IIa Study of EVER001 to Treat Primary Membranous Nephropathy

  • December 4, 2024
Everest Medicines Report the NDA Acceptance of Nefecon by the Taiwan FDA for the Treatment of Primary IgA Nephropathy

Everest Medicines Report the NDA Acceptance of Nefecon by the Taiwan FDA for the Treatment of Primary IgA Nephropathy

  • December 27, 2023
Pfizer’s Etrasimod Receives the US FDA’s Approval for Adults with Moderately to Severely Active Ulcerative Colitis

Pfizer’s Etrasimod Receives the US FDA’s Approval for Adults with Moderately to Severely Active Ulcerative Colitis

  • October 17, 2023
Everest Medicines Receives the NMPA Recommendation of Priority Review for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections

Everest Medicines Receives the NMPA Recommendation of Priority Review for Cefepime-Taniborbactam to Treat Complicated Urinary Trac...

  • September 20, 2023
Everest Medicines Partner Calliditas Publish P-III (NeflgArd) Trial Results of Nefecon for Primary IgA Nephropathy in The Lancet

Everest Medicines Partner Calliditas Publish P-III (NeflgArd) Trial Results of Nefecon for Primary IgA Nephropathy in The Lancet

  • August 18, 2023
PharmaShots Weekly Snapshots (July 24 – 28, 2023)

PharmaShots Weekly Snapshots (July 24 – 28, 2023)

  • July 29, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.